EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations

Ingmar Bergs, Katja S Just, Catharina Scholl, Michael Dreher, Julia C Stingl

European Journal of Clinical Pharmacology · 2023-02 · 79 (2) · 219-227

DOI: 10.1007/s00228-022-03433-9 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 09.12.2022. Verfasst von Ingmar Bergs und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany. ibergs@ukaachen.de. Hauptthemen laut MEDLINE: Deglutition Disorders, Drug-Related Side Effects and Adverse Reactions, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Gesundheit, RWTH Aachen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Inhaled drugs have been cornerstones in the treatment of chronic obstructive pulmonary disease (COPD) for decades and show a high prescription volume. Due to the local application, drug safety issues of these therapies are often underestimated by professionals and patients. Data about adverse drug reactions (ADRs) caused by inhaled therapy in patients with COPD and polypharmacy are rare. We aimed to analyze the use and relevance of inhaled therapies in those patients in relation to ADR complaints, which were severe enough to warrant presentation to the emergency department.

Methods

Emergency department cases due to suspected ADRs of the ADRED database ( n = 2939, “Adverse Drug Reactions in Emergency Departments”; DRKS-ID: DRKS00008979, registration date 01/11/2017) were analyzed for inhaled drugs in patients with COPD. ADRs in cases with overdosed inhaled drugs were compared to non-overdosed cases. ADRs, potentially caused by inhaled drugs, were evaluated, clustered into complexes, and assessed for association with inhaled drug classes.

Results

Of the 269 included COPD cases, 67% ( n = 180) received inhaled therapy. In 16% ( n = 28), these therapies were overdosed. Overdosed cases presented the complexes of malaise and local symptoms more frequently. Related to the use of inhaled anticholinergics, local (dysphagia-like) and related to inhaled beta-2 agonists, local (dysphagia-like) and sympathomimetic-like ADRs presented more frequently.

Conclusion

Overdosed inhaled therapies in patients with COPD lead to relevant ADRs and impact on emergency room presentations. These are rarely associated to inhaled therapy by healthcare professionals or patients. Due to the high volume of inhaled drug prescriptions, pharmacovigilance and patient education should be more focused in patients with COPD. German Clinical Trial Register : DRKS‐ID: DRKS00008979

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deglutition DisordersDrug-Related Side Effects and Adverse ReactionsPulmonary Disease, Chronic ObstructiveHumansEmergency Service, HospitalRespiratory Therapy

Stichwörter der Autor:innen

Adverse drug reactionCOPDClinical pharmacologyEmergency departmentInhaled medications

Autor:innen und Institutionen

  • Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany. ibergs@ukaachen.de.
  • Institute for Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany. ibergs@ukaachen.de.
  • Institute for Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany.
  • Research Department, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
  • Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany.

Förderung

  • Bundesministerium für Gesundheit
  • RWTH Aachen University

Zitieren

APA

Bergs, I., Just, K. S., Scholl, C., Dreher, M., & Stingl, J. C. (2023). Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations. European Journal of Clinical Pharmacology, 79(2), 219-227. https://doi.org/10.1007/s00228-022-03433-9

Vancouver

Bergs I, Just KS, Scholl C, Dreher M, Stingl JC. Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations. European Journal of Clinical Pharmacology. 2023;79(2):219-227. doi:10.1007/s00228-022-03433-9

BibTeX
@article{Bergs2023,
  author = {Bergs, Ingmar and Just, Katja S and Scholl, Catharina and Dreher, Michael and Stingl, Julia C},
  title = {Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations},
  journal = {European Journal of Clinical Pharmacology},
  year = {2023},
  volume = {79},
  number = {2},
  pages = {219--227},
  doi = {10.1007/s00228-022-03433-9}
}
Kostenlos starten →